boost-话题@MedSci

#boost#

3篇内容 | 265人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1780441, encodeId=25a41e80441eb, content=<a href='/topic/show?id=4ccb36214c' target=_blank style='color:#2F92EE;'>#boost#</a>, objectTitle= 医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据 , objectType=article, longId=292170, objectId=fea32921e0d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fea32921e0d2, replyNumber=0, likeNumber=47, createdTime=2022-08-02, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fea32921e0d2, moduleTitle= 医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fea32921e0d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780440, encodeId=2edd1e804408d, content=<a href='/topic/show?id=4ccb36214c' target=_blank style='color:#2F92EE;'>#boost#</a>, objectTitle=医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据, objectType=article, longId=209349, objectId=deee20934998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=deee20934998, replyNumber=0, likeNumber=45, createdTime=2022-01-24, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=deee20934998, moduleTitle=医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deee20934998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1780439, encodeId=de511e80439a1, content=<a href='/topic/show?id=4ccb36214c' target=_blank style='color:#2F92EE;'>#boost#</a>, objectTitle=Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究, objectType=article, longId=146130, objectId=8c0f14613063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0f14613063, replyNumber=0, likeNumber=40, createdTime=2018-08-25, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0f14613063, moduleTitle=Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c0f14613063)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

boost

2020-05-29

ms9833124466084992 (审核中...)

前往app查看评论内容

#boost#

医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据

2022-08-02

ms9833124466084992 (审核中...)

前往app查看评论内容

#boost#

医美前沿解读 | Skinbooster韩国研究-改善皮肤质量的证据

2022-01-24

ms9833124466084992 (审核中...)

前往app查看评论内容

#boost#

Eiger制药宣布首例患者入组聚乙二醇化干扰素联合Ritonavir-Boosted Lonafarnib的II期LIFT研究

2018-08-25

科室
- - 订阅+
  - 更多科室
工具
服务